The Assessment of Movement Disorders Utilizing Live Two-Way Video

Learn more about:
Related Clinical Trial
Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine Dysport for the Treatment of OMD Validation of the Implantation of a New Electrode for the Treatment of Dystonia Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia D-Serine Treatment For Tardive Dyskinesia Deep Brain Stimulation for Patients With Tardive Dyskinesia and or Dystonia Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia Levetiracetam Treatment of Tardive Dyskinesia The Assessment of Movement Disorders Utilizing Live Two-Way Video Real‐World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents Xenazine in Late Dyskinetic Syndrome With Neuroleptics Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia Effect of tDCS on Cognition, Symptoms in Chronic Schizophrenia Patients With Tardive Dyskinesia Melatonin Treatment for Tardive Dyskinesia in Schizophrenia Extract of Ginkgo Biloba and Tardive Dyskinesia Aim to Reduce Movements in Tardive Dyskinesia Reducing Involuntary Movements in Tardive Dyskinesia A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia Pyridoxal Kinase Activity in Tardive Dyskinesia Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study) NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia. Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia Piracetam for Treatment Tardive Dyskinesia Treatment of Tardive Dyskinesia With Galantamine Tardive Dyskinesia and Cognitive Function Safety and Efficacy of Pyridoxal 5′ -Phosphate in the Treatment of Tardive Dyskinesia Addressing Involuntary Movements in Tardive Dyskinesia Efficacy of Docosahexaenoic Acid on Tardive Dyskinesia

Brief Title

The Assessment of Movement Disorders Utilizing Live Two-Way Video

Official Title

The Assessment of Movement Disorders Utilizing Live Two-Way Video

Brief Summary

      The purpose of this project is to determine the equivalency of extrapyramidal symptoms (EPS)
      and tardive dyskinesia (TD) examinations conducted via live two-way video versus live
      examinations completed in-person
    

Detailed Description

      Extrapyramidal symptoms (EPS) and tardive dyskinesia (TD) are one of the most frequent and
      troublesome adverse events when taking antipsychotic agents. The investigators aim in this
      study to determine if the investigators can conduct examinations for EPS and TD remotely
      using live two-way video. It is potentially beneficial for patients, especially those who are
      located far away from psychiatrists if they could be seen by trained clinicians and assessed
      for EPS and TD via two-way video in the future. Participants will be asked to have a medical
      assessment which consists of simple questions and some examination of their movements via
      two-way video and in person. The investigators will compare the results of video examinations
      with the results of live examinations.
    


Study Type

Observational


Primary Outcome

Abnormal Involuntary Movement Scale (AIMS) when done in-person versus via two-way video

Secondary Outcome

 the correlation between the short version and full version of the Modified Simpson Angus Scale (mSAS)

Condition

Tardive Dyskinesia

Intervention

Two way video assessment

Study Arms / Comparison Groups

 schizophrenia
Description:  Inclusion Criteria: Inpatients and outpatients aged 18-75 years old who have been taking antipsychotics for longer than 6 months in their life time, and that have been compliant for the past week. Patients will be referred by their treating doctors if they have some evidence of movement disorder based on the physician's clinical judgment. We will also include 25% of the sample without any evidence of movement disorder.
Exclusion Criteria: Patients who have medical conditions which make it difficult to perform a physical examination. Patients who are clinically too ill to consent and/or unable to cooperate with the examination procedures.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Other

Estimated Enrollment

37

Start Date

November 2011

Completion Date

June 2016

Primary Completion Date

June 2016

Eligibility Criteria

        Inclusion Criteria:

          -  Inpatients and outpatients aged 18-75 years old who have been taking antipsychotics
             for longer than 6 months in their life time, and

          -  That have been compliant for the past week.

        Exclusion Criteria:

          -  Patients who have medical conditions which make it difficult to perform a physical
             examination.

          -  Patients who are clinically too ill to consent and/or unable to cooperate with the
             examination procedures.
      

Gender

All

Ages

18 Years - 75 Years

Accepts Healthy Volunteers

No

Contacts

Sandeep Kapoor, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT01467089

Organization ID

11-243B


Responsible Party

Principal Investigator

Study Sponsor

Northwell Health


Study Sponsor

Sandeep Kapoor, MD, Principal Investigator, Northwell Health


Verification Date

September 2016